STOCK TITAN

Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

KYTX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
71 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
-32.5% close of December 17, 2025
1-year change
-46.9% closing prices, November 19, 2025 to November 19, 2026
1-month change
-25% closing prices, October 19, 2026 to November 19, 2026

Company Description

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. According to the company’s public statements, Kyverna aims to "liberate" autoimmune patients by using the curative potential of cell therapy, with an emphasis on chimeric antigen receptor T-cell (CAR T) approaches targeting B-cell-driven autoimmune conditions.

Kyverna’s lead program centers on mivocabtagene autoleucel (miv-cel, KYV-101), described as a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. The company states that miv-cel is designed for potency and tolerability and is under investigation across multiple autoimmune diseases. With a single administration, miv-cel is intended to achieve deep B-cell depletion and an immune system reset that may support durable, drug-free, disease-free remission in autoimmune diseases.

Neuroimmunology franchise and key indications

Kyverna highlights a potentially first-in-class neuroimmunology franchise built around miv-cel/KYV-101. The company reports a recently completed registrational trial in stiff person syndrome (SPS), a rare, progressive neurologic autoimmune disease characterized by muscle stiffness, painful spasms, and progressive disability. In its KYSA-8 registrational Phase 2 trial in SPS, Kyverna announced positive topline data showing statistically significant clinical benefit across primary and secondary endpoints, with a single dose of miv-cel and a safety profile without high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Based on these data, Kyverna has communicated plans to submit a Biologics License Application (BLA) for SPS.

In generalized myasthenia gravis (gMG), an antibody-mediated neuromuscular autoimmune disease, Kyverna is conducting the KYSA-6 registrational Phase 2/3 trial of KYV-101. Interim Phase 2 data reported by the company indicated that all enrolled patients achieved clinically meaningful reductions in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores after a single dose, with no high-grade CRS or ICANS observed. Kyverna has also reported initiation of the Phase 3 portion of this trial and describes gMG as a core late-stage indication within its neuroimmunology strategy.

Broader autoimmune pipeline and KYSA trials

Beyond SPS and gMG, Kyverna is using sponsored clinical trials and investigator-initiated trials (IITs) to evaluate KYV-101 in additional autoimmune diseases. Company disclosures reference clinical work in lupus nephritis through multi-center Phase 1/2 trials, as well as IITs in multiple sclerosis and rheumatoid arthritis. Data presented from these efforts, including at neurology and rheumatology conferences, are described by the company as informing indication-expansion priorities and the next autoimmune diseases to advance into late-stage development.

Kyverna also refers to a series of KYSA-branded trials that support its development plans. These include KYSA-8 in SPS and KYSA-6 in gMG, along with other KYSA studies and investigator-led efforts in additional autoimmune conditions. The company positions these programs as a way to build a body of evidence around the role of CD19-targeted CAR T-cell therapy in B-cell-driven autoimmune disease.

Next-generation programs and manufacturing innovation

In addition to autologous KYV-101/miv-cel, Kyverna is developing a next-generation pipeline of CAR T-cell therapies. Public materials describe both autologous and allogeneic formats, with the goal of expanding into broader autoimmune indications and improving patient access and experience. A notable program is KYV-102, which the company characterizes as using a proprietary whole blood, rapid manufacturing process and incorporating the same CAR construct as KYV-101. According to Kyverna, KYV-102 is intended to broaden access by eliminating apheresis and potentially reducing the cost of goods, while supporting expansion into additional autoimmune diseases.

Kyverna also references the development of manufacturing approaches and clinical strategies that explore options such as alternative lymphodepletion regimens and outpatient administration for miv-cel, as well as continued evaluation of additional pipeline opportunities in what it describes as a capital-efficient manner.

Corporate profile and capital strategy

Kyverna Therapeutics is listed on The Nasdaq Stock Market LLC under the ticker symbol KYTX. The company identifies itself as an emerging growth company and a clinical-stage biopharmaceutical issuer. It has used a combination of public equity offerings and debt financing to support its development plans. For example, Kyverna entered into a loan and security agreement with Oxford Finance LLC for a term loan facility of up to a stated principal amount, and it has completed an underwritten public offering of common stock pursuant to an effective shelf registration statement on Form S-3.

In its communications, Kyverna links its capital strategy directly to funding late-stage clinical programs in SPS and gMG, as well as pre-launch and potential commercialization activities. The company has also reported that follow-on offerings and loan facilities are intended to extend its cash runway to support regulatory submissions, a potential commercial launch in SPS, and continued advancement of its Phase 3 gMG trial and pipeline programs.

Leadership and governance developments

Kyverna’s SEC filings document changes in its board and leadership structure. The company reported the appointment of Christi Shaw, previously an independent director, as Executive Chairperson of the Board, with the prior Chairperson remaining on the board as a director. The related offer letter describes equity-based compensation in the form of stock options, restricted stock units, and performance-based restricted stock units tied to share price targets, as well as change-in-control vesting provisions. Other filings note board-level changes, such as the resignation of a director and corresponding adjustments to board size and committee assignments.

These governance disclosures, together with Kyverna’s regular financial reporting and Regulation FD communications, provide insight into how the company is organizing its leadership and capital structure to pursue its stated objective of advancing CAR T-cell therapies for autoimmune diseases.

Focus on autoimmune CAR T-cell therapy

Across its public statements, Kyverna consistently characterizes itself as a company focused on autoimmune CAR T-cell therapy. It emphasizes B-cell-driven autoimmune diseases, the potential for single-dose treatments that may reduce or eliminate chronic immunotherapies, and the goal of building a neuroimmunology franchise. Investors and observers evaluating KYTX can review Kyverna’s press releases, clinical trial updates, and SEC filings to track progress on registrational trials, regulatory interactions, financing activities, and governance developments.

Stock Performance

$4.89
+12.00%
+0.52
After hoursChange vs the $4.37 closeLast updated: at
-46.9%
Performance 1 year
$309.4M

Kyverna Therapeutics (KYTX) closed at $4.37 on November 19, 2026. Over the past 12 months, the price has lost 46.9%.

See what a $1,000 investment in KYTX would be worth today

Average down calculator for KYTX

KYTX Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Kyverna Therapeutics has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, clinical trial, conferences. View all KYTX news →

Financial Highlights

Kyverna Therapeutics reported operating income of -$169.8M in FY2025, and net income was -$161.3M. Diluted earnings per share stood at -$3.64. The company generated -$153.7M in operating cash flow. The current ratio was 7.75, measuring current assets divided by current liabilities.

-$161.3M
Net Income (FY2025)
-$153.7M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
19
November 19, 2026 Marketing

Jefferies presentation

Presentation at Jefferies Global Healthcare Conference in London on 2026-11-19 10:00 GMT. Webcast: ir.kyvernatx.com; replay ~90 days.
Q4
2026
Q4 2026 Product

Commercial launch of miv-cel

Planned commercial launch of miv-cel (KYV-101) by year-end 2026
YEAR
2027
2027 Corporate

Development strategy update

Kyverna to provide a development-strategy update for miv-cel and its RMAT pathway; scheduled in early 2027 (Jan–Apr).
YEAR
2027
2027 Product

Potential product launch

Contingent commercial launch of miv-cel for stiff person syndrome in 2027, subject to FDA approval and priority review timing.
YEAR
2027
2027 Clinical

gMG Phase 3 enrollment

Projected start of enrollment for the myasthenia gravis (gMG) Phase 3 trial in mid-2027 (May–Aug); sites/details TBA.
YEAR
2027
2027 Clinical

KYSA-6 enrollment completion

Company aims to complete enrollment in the KYSA-6 Phase 3 gMG trial by mid-2027; expected May–Aug 2027 window.
YEAR
2027
2027 Clinical

Phase 3 enrollment completion

Expected completion of Phase 3 generalized myasthenia gravis enrollment in mid-2027 (May–Aug 2027 window) per company guidance.
OCT
01
October 1, 2030 Financial

Debt facility maturity

Maturity of up to $150M Oxford Finance debt facility

Kyverna Therapeutics has 8 upcoming scheduled events. The next event, "Jefferies presentation", is scheduled for November 19, 2026 (today). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the KYTX stock price.

Short Interest History

Last 12 Months

Short interest in Kyverna Therapeutics (KYTX) currently stands at 9.1 million shares, down 4.7% from the previous reporting period, representing 16.2% of the float. Since November 2025, short interest has increased by 157.6%.

Days to Cover History

Last 12 Months

Days to cover for Kyverna Therapeutics (KYTX) currently stands at 11.6 days, up 10.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 82.4%. Across the settlements charted above, it has ranged from 1.2 to 13.3 days.

KYTX Company Profile & Sector Positioning

Kyverna Therapeutics (KYTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing KYTX often look at related companies in the same sector, including Altimmune, Inc. (ALT), X4 Pharmaceuticals, Inc. (XFOR), Lyell Immunopharma, Inc. (LYEL), Enanta Pharmaceuticals, Inc (ENTA), and Larimar Therapeutics, Inc. (LRMR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KYTX's relative position within its industry.

Frequently Asked Questions

The current stock price of Kyverna Therapeutics (KYTX) is $4.89 in after-hours trading as of November 19, 2026.

The market cap of Kyverna Therapeutics (KYTX) is approximately $309.4M. Learn more about what market capitalization means .

The FY2025 net income of Kyverna Therapeutics (KYTX) is -$161.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Kyverna Therapeutics (KYTX) is -$3.64 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Kyverna Therapeutics (KYTX) is -$153.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Kyverna Therapeutics (KYTX), current assets divided by current liabilities, was 7.75 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Kyverna Therapeutics (KYTX) is -$169.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company that states it is focused on developing cell therapies for patients with autoimmune diseases. Its programs center on CD19-targeting CAR T-cell therapies designed to address B-cell-driven autoimmune conditions.

According to Kyverna, KYV-101, also referred to as mivocabtagene autoleucel or miv-cel, is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is under investigation for B-cell-driven autoimmune diseases and is intended to achieve deep B-cell depletion and an immune system reset with a single administration.

Company disclosures highlight stiff person syndrome and generalized myasthenia gravis as key late-stage indications for miv-cel/KYV-101, with a completed registrational trial in stiff person syndrome and a registrational Phase 2/3 trial in generalized myasthenia gravis. Kyverna also references clinical work in lupus nephritis and investigator-initiated trials in multiple sclerosis and rheumatoid arthritis.

Kyverna describes its neuroimmunology franchise as a potentially first-in-class portfolio built around CD19-targeting CAR T-cell therapy for neurologic autoimmune diseases. This franchise includes registrational programs in stiff person syndrome and generalized myasthenia gravis, along with additional studies intended to inform expansion into other neuroimmunology indications.

KYV-102 is described by Kyverna as a next-generation CAR T-cell therapy that uses the same CAR construct as KYV-101 but is produced with a proprietary whole blood, rapid manufacturing process. The company states that KYV-102 is intended to broaden access by eliminating apheresis and potentially reducing the cost of goods, while supporting expansion into broader autoimmune indications.

Kyverna Therapeutics, Inc. reports that its common stock is listed on The Nasdaq Stock Market LLC under the ticker symbol KYTX. This information appears in multiple Form 8-K filings describing the company’s registered securities.

Kyverna’s SEC filings describe the use of public equity offerings and a term loan facility to fund its activities. The company entered into an underwriting agreement for an underwritten public offering of common stock under an effective shelf registration statement and also secured a loan and security agreement with Oxford Finance LLC for a term loan facility, which it links to supporting late-stage programs and pre-launch activities.

In a Form 8-K, Kyverna reported that its board appointed Christi Shaw, previously a board member, as Executive Chairperson of the Board. The filing outlines her compensation arrangements, equity awards, and change-in-control provisions. Other filings note a director resignation, a corresponding reduction in board size, and committee reassignments.

KYSA-8 is described as a registrational Phase 2 trial of mivocabtagene autoleucel in stiff person syndrome, for which Kyverna has announced positive topline data. KYSA-6 is a registrational Phase 2/3 trial of KYV-101 in generalized myasthenia gravis, where interim Phase 2 data showed clinically meaningful improvements in disease scores and a safety profile without high-grade CRS or ICANS, according to the company.

Kyverna states that it is harnessing KYSA trials and investigator-initiated trials in conditions such as multiple sclerosis and rheumatoid arthritis to inform the next priority indications. The company also notes that it evaluates additional pipeline opportunities in a capital-efficient manner and is developing next-generation CAR T-cell therapies in both autologous and allogeneic formats.